Jared K. Lunceford, Ph.D.
Affiliations: | 2001 | North Carolina State University, Raleigh, NC |
Area:
StatisticsGoogle:
"Jared Lunceford"Parents
Sign in to add mentor| Marie Davidian | grad student | 2001 | NCSU | |
| (Estimating causal treatment effects via the propensity score and estimating survival distributions in clinical trials that follow two-stage randomization designs.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fléchon A, Morales-Barrera R, Powles T, et al. (2024) Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF12 |
| Shah MA, Kojima T, Hochhauser D, et al. (2022) T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncology (London, England) |
| Bellmunt J, de Wit R, Fradet Y, et al. (2022) Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Winer EP, Lipatov O, Im S, et al. (2020) Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. Journal of Clinical Oncology. 38: 1013-1013 |
| Cho BC, Lopes G, Kowalski DM, et al. (2020) Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC Cancer Research. 80 |
| Daud A, Carlino MS, Ribas A, et al. (2020) Abstract 2009: Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma Clinical Trials. 80: 2009-2009 |
| Grivas P, Castellano DE, O'Donnell PH, et al. (2019) Association between stromal/TGF-β/EMT gene expression signature and response to pembrolizumab monotherapy in cisplatin-ineligible patients with locally advanced (unresectable) or metastatic urothelial carcinoma. Journal of Clinical Oncology. 37: 433-433 |
| Loi S, Schmid P, Cortés J, et al. (2019) Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 Cancer Research. 79 |
| Ribas A, Robert C, Schachter J, et al. (2019) Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study Cancer Research. 79: 4217-4217 |
| Herbst RS, Lopes G, Kowalski DM, et al. (2019) LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 Annals of Oncology. 30 |